Fondaparinux indications: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Fondaparinux indications" [edit=sysop:move=sysop]) |
No edit summary |
||
| Line 13: | Line 13: | ||
* the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium, and | * the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium, and | ||
* the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. | * the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital. | ||
{{FDA}} | |||
[[Category:Drugs]] | |||
Revision as of 19:02, 14 February 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Fondaparinux sodium (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:
- in patients undergoing hip fracture surgery, including extended prophylaxis;
- in patients undergoing hip replacement surgery;
- in patients undergoing knee replacement surgery;
- in patients undergoing abdominal surgery who are at risk for thromboembolic complications.
Fondaparinux sodium (Arixtra) Injection is indicated for:
- the treatment of acute deep vein thrombosis when administered in conjunction with warfarin sodium, and
- the treatment of acute pulmonary embolism when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
Adapted from the FDA Package Insert.